NEBCIN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jun 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEBCIN is an injectable small-molecule antibiotic approved in 1979 by Eli Lilly. The specific indication and mechanism of action are not publicly documented in available data. It is administered via injection for treating bacterial infections.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team right-sizing or transition planning within the next 1–3 years.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NEBCIN offers limited career growth opportunities given its approaching LOE and zero linked job openings. Roles on this product are primarily defensive (managed care negotiations, generic transition planning) rather than growth-oriented.
Brand ManagerProduct Manager
Worked on NEBCIN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.